<p class="MarginalNote"><span class="wb-invisible">Marginal note:</span>Authorization</p><ul class="Section ProvisionList" id="412417"><li><p class="Subsection" id="412419"><strong><a class="sectionLabel" id="s-21.04"><span class="sectionLabel">21.04</span></a></strong> <span class="lawlabel">(1)</span> Subject to subsection (3), the Commissioner shall, on the application of any person and on the payment of the prescribed fee, authorize the person to make, construct and use a patented invention solely for purposes directly related to the manufacture of the pharmaceutical product named in the application and to sell it for export to a country or WTO Member that is listed in any of Schedules 2 to 4 and that is named in the application.</p></li><li><p class="MarginalNote"><span class="wb-invisible">Marginal note:</span>Contents of application</p><p class="Subsection" id="412420"><span class="lawlabel">(2)</span> The application must be in the prescribed form and set out</p><ul class="ProvisionList"><li><p class="Paragraph" id="412422"><span class="lawlabel">(a)</span> the name of the pharmaceutical product to be manufactured and sold for export under the authorization;</p></li><li><p class="Paragraph" id="412423"><span class="lawlabel">(b)</span> prescribed information in respect of the version of the pharmaceutical product to be manufactured and sold for export under the authorization;</p></li><li><p class="Paragraph" id="412424"><span class="lawlabel">(c)</span> the maximum quantity of the pharmaceutical product to be manufactured and sold for export under the authorization;</p></li><li><p class="Paragraph" id="412425"><span class="lawlabel">(d)</span> for each patented invention to which the application relates, the name of the patentee of the invention and the number, as recorded in the Patent Office, of the patent issued in respect of that invention;</p></li><li><p class="Paragraph" id="412426"><span class="lawlabel">(e)</span> the name of the country or WTO Member to which the pharmaceutical product is to be exported;</p></li><li><p class="Paragraph" id="412427"><span class="lawlabel">(f)</span> the name of the governmental person or entity, or the person or entity permitted by the government of the importing country, to which the product is to be sold, and prescribed information, if any, concerning that person or entity; and</p></li><li><p class="Paragraph" id="412428"><span class="lawlabel">(g)</span> any other information that may be prescribed.</p></li></ul></li><li><p class="MarginalNote"><span class="wb-invisible">Marginal note:</span>Conditions for granting of authorization</p><p class="Subsection" id="412429"><span class="lawlabel">(3)</span> The Commissioner shall authorize the use of the patented invention only if</p><ul class="ProvisionList"><li><p class="Paragraph" id="412431"><span class="lawlabel">(a)</span> the applicant has complied with the prescribed requirements, if any;</p></li><li><p class="Paragraph" id="412432"><span class="lawlabel">(b)</span> the Minister of Health has notified the Commissioner that the version of the pharmaceutical product that is named in the application meets the requirements of the <cite class="XRefExternalAct"><a href="/eng/acts/F-27">Food and Drugs Act</a></cite> and its regulations, including the requirements under those regulations relating to the marking, embossing, labelling and packaging that identify that version of the product as having been manufactured</p><ul class="ProvisionList"><li><p class="Subparagraph" id="412433"><span class="lawlabel">(i)</span> in Canada as permitted by the General Council Decision, and</p></li><li><p class="Subparagraph" id="412434"><span class="lawlabel">(ii)</span> in a manner that distinguishes it from the version of the pharmaceutical product sold in Canada by, or with the consent of, the patentee or patentees, as the case may be;</p></li></ul></li><li><p class="Paragraph" id="412435"><span class="lawlabel">(c)</span> the applicant provides the Commissioner with a solemn or statutory declaration in the prescribed form stating that the applicant had, at least thirty days before filing the application,</p><ul class="ProvisionList"><li><p class="Subparagraph" id="412436"><span class="lawlabel">(i)</span> sought from the patentee or, if there is more than one, from each of the patentees, by certified or registered mail, a licence to manufacture and sell the pharmaceutical product for export to the country or WTO Member named in the application on reasonable terms and conditions and that such efforts have not been successful, and</p></li><li><p class="Subparagraph" id="412437"><span class="lawlabel">(ii)</span> provided the patentee, or each of the patentees, as the case may be, by certified or registered mail, in the written request for a licence, with the information that is in all material respects identical to the information referred to in paragraphs (2)(a) to (g); and</p></li></ul></li><li><p class="Paragraph" id="412438"><span class="lawlabel">(d)</span> the applicant also provides the Commissioner with</p><ul class="ProvisionList"><li><p class="Subparagraph" id="412439"><span class="lawlabel">(i)</span> if the application relates to a WTO Member listed in Schedule 2, a certified copy of the notice in writing that the WTO Member has provided to the TRIPS Council specifying the name of the pharmaceutical product, as defined in paragraph 1(a) of the General Council Decision, and the quantity of that product, needed by the WTO Member, and</p><ul class="ProvisionList"><li><p class="Clause" id="412440"><span class="lawlabel">(A)</span> a solemn or statutory declaration in the prescribed form by the person filing the application stating that the product to which the application relates is the product specified in the notice and that the product is not patented in that WTO Member, or</p></li><li><p class="Clause" id="412441"><span class="lawlabel">(B)</span> a solemn or statutory declaration in the prescribed form by the person filing the application stating that the product to which the application relates is the product specified in the notice and a certified copy of the notice in writing that the WTO Member has provided to the TRIPS Council confirming that the WTO Member has, in accordance with Article 31 of the TRIPS Agreement and the provisions of the General Council Decision, granted or intends to grant a compulsory licence to use the invention pertaining to the product,</p></li></ul></li><li><p class="Subparagraph" id="412442"><span class="lawlabel">(ii)</span> if the application relates to a country listed in Schedule 2 that is not a WTO Member, a certified copy of the notice in writing that the country has provided to the Government of Canada through diplomatic channels specifying the name of the pharmaceutical product, as defined in paragraph 1(a) of the General Council Decision, and the quantity of that product, needed by the country, and</p><ul class="ProvisionList"><li><p class="Clause" id="412443"><span class="lawlabel">(A)</span> a solemn or statutory declaration in the prescribed form by the person filing the application stating that the product to which the application relates is the product specified in the notice and that the product is not patented in that country, or</p></li><li><p class="Clause" id="412444"><span class="lawlabel">(B)</span> a solemn or statutory declaration in the prescribed form by the person filing the application stating that the product to which the application relates is the product specified in the notice and a certified copy of the notice in writing that the country has provided to the Government of Canada through diplomatic channels confirming that the country has granted or intends to grant a compulsory licence to use the invention pertaining to the product,</p></li></ul></li><li><p class="Subparagraph" id="412445"><span class="lawlabel">(iii)</span> if the application relates to a WTO Member listed in Schedule 3, a certified copy of the notice in writing that the WTO Member has provided to the TRIPS Council specifying the name of the pharmaceutical product, as defined in paragraph 1(a) of the General Council Decision, and the quantity of that product, needed by the WTO Member, and stating that the WTO Member has insufficient or no pharmaceutical manufacturing capacity for the production of the product to which the application relates, and</p><ul class="ProvisionList"><li><p class="Clause" id="412446"><span class="lawlabel">(A)</span> a solemn or statutory declaration in the prescribed form by the person filing the application stating that the product to which the application relates is not patented in that WTO Member, or</p></li><li><p class="Clause" id="412447"><span class="lawlabel">(B)</span> a certified copy of the notice in writing that the WTO Member has provided to the TRIPS Council confirming that the WTO Member has, in accordance with Article 31 of the TRIPS Agreement and the provisions of the General Council Decision, granted or intends to grant a compulsory licence to use the invention pertaining to the product,</p></li></ul></li><li><p class="Subparagraph" id="412448"><span class="lawlabel">(iv)</span> if the application relates to a WTO Member listed in Schedule 4, a certified copy of the notice in writing that the WTO Member has provided to the TRIPS Council specifying the name of the pharmaceutical product, as defined in paragraph 1(a) of the General Council Decision, and the quantity of that product, needed by the WTO Member, and stating that the WTO Member is faced with a national emergency or other circumstances of extreme urgency and that it has insufficient or no pharmaceutical manufacturing capacity for the production of the product to which the application relates, and</p><ul class="ProvisionList"><li><p class="Clause" id="412449"><span class="lawlabel">(A)</span> a solemn or statutory declaration in the prescribed form by the person filing the application stating that the product to which the application relates is not patented in that WTO Member, or</p></li><li><p class="Clause" id="412450"><span class="lawlabel">(B)</span> a certified copy of the notice in writing that the WTO Member has provided to the TRIPS Council confirming that the WTO Member has, in accordance with Article 31 of the TRIPS Agreement and the provisions of the General Council Decision, granted or intends to grant a compulsory licence to use the invention pertaining to the product, or</p></li></ul></li><li><p class="Subparagraph" id="412451"><span class="lawlabel">(v)</span> if the application relates to a country listed in Schedule 4 that is not a WTO Member, a certified copy of the notice in writing that the country has provided to the Government of Canada through diplomatic channels specifying the name of the pharmaceutical product, as defined in paragraph 1(a) of the General Council Decision, and the quantity of that product, needed by the country, and stating that it is faced with a national emergency or other circumstances of extreme urgency, that it has insufficient or no pharmaceutical manufacturing capacity for the production of the product to which the application relates, that it agrees that product will not be used for commercial purposes and that it undertakes to adopt the measures referred to in Article 4 of the General Council Decision, and</p><ul class="ProvisionList"><li><p class="Clause" id="412452"><span class="lawlabel">(A)</span> a solemn or statutory declaration in the prescribed form by the person filing the application stating that the product to which the application relates is not patented in that country, or</p></li><li><p class="Clause" id="412453"><span class="lawlabel">(B)</span> a certified copy of the notice in writing that the country has provided to the Government of Canada through diplomatic channels confirming that the country has granted or intends to grant a compulsory licence to use the invention pertaining to the product.</p></li></ul></li></ul></li></ul></li></ul><div class="HistoricalNote"><ul class="HistoricalNote"><li class="HistoricalNoteSubItem">2004, c. 23, s. 1</li></ul></div>